Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
(
1 selected
)
Type
Guidance (363)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (24)
Diagnostics guidance (5)
Health technology evaluations (14)
Highly specialised technologies guidance (7)
Interventional procedures guidance (19)
Medical technologies guidance (10)
NICE guidelines (28)
Public health guidelines (1)
Technology appraisal guidance (286)
Apply filters
Showing 351 to 360 of 363
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Vosoritide for treating achondroplasia in people 4 months and over ID6488
Technology appraisal guidance
TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Highly specialised technology
TBC
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]
Technology appraisal guidance
28 January 2026
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
Technology appraisal guidance
22 November 2017
Women's and reproductive health guidelines
NICE guideline
TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]
Technology appraisal guidance
TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]
Technology appraisal guidance
14 May 2026
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Technology appraisal guidance
20 August 2025
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Technology appraisal guidance
TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
Technology appraisal guidance
TBC
Previous page
1
…
34
35
Current page
36
37
Page
36
of
37
Next page
Results per page
10
25
50
All
Back to top